Zealand Pharma A/S (ZEAL) - Net Assets

Latest as of December 2025: Dkr14.83 Billion DKK ≈ $2.32 Billion USD

Based on the latest financial reports, Zealand Pharma A/S (ZEAL) has net assets worth Dkr14.83 Billion DKK (≈ $2.32 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr16.46 Billion ≈ $2.58 Billion USD) and total liabilities (Dkr1.63 Billion ≈ $255.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zealand Pharma A/S liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Dkr14.83 Billion
% of Total Assets	90.09%
Annual Growth Rate	25.68%
5-Year Change	1498.47%
10-Year Change	5231.03%
Growth Volatility	112.97

Zealand Pharma A/S - Net Assets Trend (2007–2025)

This chart illustrates how Zealand Pharma A/S's net assets have evolved over time, based on quarterly financial data. Also explore Zealand Pharma A/S (ZEAL) total assets for the complete picture of this company's asset base.

Annual Net Assets for Zealand Pharma A/S (2007–2025)

The table below shows the annual net assets of Zealand Pharma A/S from 2007 to 2025. For live valuation and market cap data, see Zealand Pharma A/S stock valuation.

Year	Net Assets	Change
2025-12-31	Dkr14.83 Billion ≈ $2.32 Billion	+72.11%
2024-12-31	Dkr8.62 Billion ≈ $1.35 Billion	+440.97%
2023-12-31	Dkr1.59 Billion ≈ $249.21 Million	+95.22%
2022-12-31	Dkr815.91 Million ≈ $127.66 Million	-12.06%
2021-12-31	Dkr927.80 Million ≈ $145.16 Million	-21.18%
2020-12-31	Dkr1.18 Billion ≈ $184.16 Million	-5.28%
2019-12-31	Dkr1.24 Billion ≈ $194.43 Million	+11.32%
2018-12-31	Dkr1.12 Billion ≈ $174.65 Million	+111.23%
2017-12-31	Dkr528.47 Million ≈ $82.68 Million	+89.96%
2016-12-31	Dkr278.19 Million ≈ $43.53 Million	+10.29%
2015-12-31	Dkr252.23 Million ≈ $39.46 Million	-0.24%
2014-12-31	Dkr252.83 Million ≈ $39.56 Million	-20.03%
2013-12-31	Dkr316.14 Million ≈ $49.46 Million	-35.61%
2012-12-31	Dkr491.01 Million ≈ $76.82 Million	+11.24%
2011-12-31	Dkr441.40 Million ≈ $69.06 Million	+8.42%
2010-12-31	Dkr407.11 Million ≈ $63.70 Million	+206.27%
2009-12-31	Dkr132.92 Million ≈ $20.80 Million	-36.29%
2008-12-31	Dkr208.63 Million ≈ $32.64 Million	-13.92%
2007-12-31	Dkr242.37 Million ≈ $37.92 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Zealand Pharma A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 97.2% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	Dkr6.29 Million	0.04%
Common Stock	Dkr71.52 Million	0.48%
Other Comprehensive Income	Dkr23.38 Million	0.16%
Other Components	Dkr14.73 Billion	99.32%
Total Equity	Dkr14.83 Billion	100.00%

Zealand Pharma A/S Competitors by Market Cap

The table below lists competitors of Zealand Pharma A/S ranked by their market capitalization.

Company	Market Cap
Camurus AB ST:CAMX	$3.41 Billion
The Marzetti Company NASDAQ:MZTI	$3.41 Billion
Organización Soriana S. A. B. de C. V MX:SORIANAB	$3.41 Billion
ChengDu Hi-Tech Development Co Ltd SHE:000628	$3.41 Billion
LIFE360 Inc AU:360	$3.40 Billion
Shanghai Jin Jiang International Hotels Development Co Ltd A SHG:600754	$3.40 Billion
Jubilant Foodworks Limited NSE:JUBLFOOD	$3.40 Billion
MiTAC Holdings Corp TW:3706	$3.40 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zealand Pharma A/S's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 8,616,742,000 to 14,830,613,000, a change of 6,213,871,000 (72.1%).
Net income of 6,455,008,000 contributed positively to equity growth.
Share repurchases of 407,170,000 reduced equity.
Other comprehensive income increased equity by 993,000.
Other factors increased equity by 165,040,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Dkr6.46 Billion	+43.52%
Share Repurchases	Dkr407.17 Million	-2.75%
Other Comprehensive Income	Dkr993.00K	+0.01%
Other Changes	Dkr165.04 Million	+1.11%
Total Change	Dkr-	72.11%

Book Value vs Market Value Analysis

This analysis compares Zealand Pharma A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.49x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 22.54x to 1.49x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2007-12-31	Dkr13.71	Dkr309.00	x
2008-12-31	Dkr11.80	Dkr309.00	x
2009-12-31	Dkr7.52	Dkr309.00	x
2010-12-31	Dkr22.37	Dkr309.00	x
2011-12-31	Dkr19.77	Dkr309.00	x
2012-12-31	Dkr21.60	Dkr309.00	x
2013-12-31	Dkr13.97	Dkr309.00	x
2014-12-31	Dkr11.17	Dkr309.00	x
2015-12-31	Dkr10.94	Dkr309.00	x
2016-12-31	Dkr11.44	Dkr309.00	x
2017-12-31	Dkr18.97	Dkr309.00	x
2018-12-31	Dkr36.37	Dkr309.00	x
2019-12-31	Dkr36.76	Dkr309.00	x
2020-12-31	Dkr30.68	Dkr309.00	x
2021-12-31	Dkr21.64	Dkr309.00	x
2022-12-31	Dkr17.66	Dkr309.00	x
2023-12-31	Dkr28.15	Dkr309.00	x
2024-12-31	Dkr129.70	Dkr309.00	x
2025-12-31	Dkr207.29	Dkr309.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zealand Pharma A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 43.52%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 70.05%
• Asset Turnover: 0.56x
• Equity Multiplier: 1.11x
Recent ROE (43.52%) is above the historical average (-34.67%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	-22.69%	-91.79%	0.23x	1.09x	Dkr-79.24 Million
2008	-16.17%	-59.96%	0.25x	1.08x	Dkr-54.60 Million
2009	-60.21%	-316.08%	0.16x	1.19x	Dkr-93.32 Million
2010	-25.70%	-119.78%	0.19x	1.11x	Dkr-145.34 Million
2011	1.54%	4.79%	0.30x	1.06x	Dkr-37.33 Million
2012	7.41%	16.27%	0.43x	1.06x	Dkr-12.73 Million
2013	-58.13%	-2795.21%	0.02x	1.10x	Dkr-215.37 Million
2014	-25.71%	-42.26%	0.26x	2.36x	Dkr-90.27 Million
2015	-45.18%	-60.72%	0.30x	2.52x	Dkr-139.18 Million
2016	-55.32%	-65.56%	0.34x	2.50x	Dkr-181.73 Million
2017	-51.52%	-194.79%	0.19x	1.40x	Dkr-325.12 Million
2018	52.07%	1530.62%	0.03x	1.10x	Dkr469.65 Million
2019	-45.99%	-1382.77%	0.03x	1.29x	Dkr-695.81 Million
2020	-71.93%	-239.65%	0.18x	1.64x	Dkr-964.44 Million
2021	-109.74%	-348.01%	0.14x	2.23x	Dkr-1.11 Billion
2022	-118.35%	-928.60%	0.07x	1.89x	Dkr-1.05 Billion
2023	-44.18%	-205.30%	0.17x	1.24x	Dkr-863.02 Million
2024	-12.52%	-1720.87%	0.01x	1.10x	Dkr-1.94 Billion
2025	43.52%	70.05%	0.56x	1.11x	Dkr4.97 Billion

Industry Comparison

This section compares Zealand Pharma A/S's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $1,661,079,000
Average return on equity (ROE) among peers: -7.35%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Zealand Pharma A/S (ZEAL)	Dkr14.83 Billion	-22.69%	0.11x	$3.41 Billion
ALK-Abelló A/S (ALK-B)	$6.45 Billion	18.57%	0.42x	$7.62 Billion
Bavarian Nordic (BAVA)	$1.02 Billion	-21.30%	0.67x	$2.30 Billion
Genmab A/S (GMAB)	$659.52 Million	17.04%	1.63x	$16.33 Billion
Gubra A/S (GUBRA)	$151.46 Million	44.85%	0.99x	$820.85 Million
Pharma Equity Group A/S Cl A (PEG)	$34.28 Million	-95.90%	0.68x	$16.36 Million

About Zealand Pharma A/S

CO:ZEAL Denmark Biotechnology

Market Cap

$3.41 Billion

Dkr21.77 Billion DKK

Market Cap Rank

#4569 Global

#26 in Denmark

Share Price

Dkr309.00

Change (1 day)

+3.21%

52-Week Range

Dkr234.90 - Dkr545.80

All Time High

Dkr954.00